Stocks · US
GH
XNAS
Guardant Health, Inc. Common Stock
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E—
P/B—
P/S21.24x
EPS$-3.38
ROE203.46%
ROA-23.71%
Dividend yield0.00%
Debt/Equity-6.74
Free cash flow$-241M
Returns and 52-week range
1W-3.96%
1M+5.75%
3M+9.30%
6M+82.95%
1Y+171.63%
YTD+67.77%
52W high$191.05
52W low$61.00
From 52W high-10.66%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Royalty Pharma plc Class A Ordinary Shares | $25.2B | 30.96 | 3.69 | -11.76% |
| 랩코프 | $25.0B | 24.97 | 2.91 | -4.64% |
| 퀘스트 다이어그노스틱스 | $25.6B | 24.20 | 3.41 | -3.69% |
| Incyte Genomics Inc | $23.1B | 14.35 | 3.65 | -11.06% |
| Roivant Sciences Ltd. Common Shares | $25.8B | — | 6.11 | +1.72% |
| United Therapeutics Corp | $23.0B | 17.55 | 3.59 | +11.08% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.